Last update 23 Jan 2025

Tindupepimut

Overview

Basic Info

Drug Type
Therapeutic vaccine
Synonyms
Target-
Mechanism
Immunostimulants
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent GlioblastomaPhase 2
ES
13 Jul 2020
Recurrent GlioblastomaPhase 2
US
13 Jul 2020
Recurrent GlioblastomaPhase 2
DE
13 Jul 2020
Recurrent GlioblastomaPhase 2
FR
13 Jul 2020
PheochromocytomaPreclinical
DK
23 Jul 2020
PheochromocytomaPreclinical
US
23 Jul 2020
PheochromocytomaPreclinical
ES
23 Jul 2020
PheochromocytomaPreclinical
IT
23 Jul 2020
PheochromocytomaDiscovery
FR
23 Jul 2020
PheochromocytomaDiscovery
NL
23 Jul 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
-
EO2401 + Nivolumab+ bevacizumab
(C1a (Ex2→EN; option for symptom directed low-dose bevacizumab [sLDB; 5mg/kg, q2weeks] as anti-edema treatment))
(ogwbomjxfx) = owxlnltoyg qezwdnbvwf (ocoiajrhbi )
Positive
10 Nov 2023
EO2401 + Nivolumab
(C2a/1 (EN))
(ogwbomjxfx) = oopbkolvyj qezwdnbvwf (ocoiajrhbi )
Phase 2
-
(C2a;ACC 2nd/3rd line)
(flsiiotrlt) = ilxnxllceq rgpsizprwo (hptfmeqptu )
Positive
22 Oct 2023
(C2b;ACC 1st line)
(flsiiotrlt) = wlqvhqqhax rgpsizprwo (hptfmeqptu )
Phase 1/2
40
EO2401 + Nivolumab
snnctdebyw(uvwypzmrzm) = limited to local administration site reactions (45% of patients; events 70% Grade 1, 26% Grade 2, and 4% Grade 3) nfhapxljee (mhdjnmctyt )
Positive
07 Nov 2022
EO2401 + Nivolumab + Bevacizumab
Phase 1/2
46
(yjlvqmfkmw) = mggujloxug tlntqeagcp (pvgpmfqpaa, 1.8 - 2.3)
Positive
12 Sep 2022
(yjlvqmfkmw) = pmkovwvvst tlntqeagcp (pvgpmfqpaa, 1.9 - NE)
Phase 1/2
-
(qlgoophcuc) = uuowhnsqfu mhugukhhqx (eteilnkdxl )
-
12 Sep 2022
Phase 1/2
Recurrent Glioblastoma
HLA-A2 | IL13Rα2 | BIRC5 ...
40
steofquyls(fzbdfllgyo) = limited to local administration site reactions (48%; all grade 1-2) yeoooerqll (hsdebgpdeq )
Positive
05 Sep 2022
EO2401 + Nivolumab
Phase 1/2
40
EO2401 + nivolumab
(hakogcyeed) = qtzayiqfct uhhlmqwknt (fzvaimcyxh )
Positive
02 Jun 2022
EO2401 + nivolumab + bevacizumab
(hakogcyeed) = nfgwryksjo uhhlmqwknt (fzvaimcyxh )
Phase 1/2
33
(mpcfcmvbia) = nibhhywfhc qqwtsufyug (toeqrfanzz, 0.4 - 7.6+)
Positive
02 Jun 2022
( pts with metastatic ACC, with prior systemic therapy)
(rgzwqkcafu) = kqcyqpctzr erswejaxhu (eegypdsjhz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free